Chronic corticosterone administration induces negative valence and impairs positive valence behaviors in mice.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
10 12 2019
10 12 2019
Historique:
received:
16
05
2019
accepted:
21
11
2019
revised:
11
11
2019
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
22
9
2020
Statut:
epublish
Résumé
Behavioral approaches utilizing rodents to study mood disorders have focused primarily on negative valence behaviors associated with potential threat (anxiety-related behaviors). However, for disorders such as depression, positive valence behaviors that assess reward processing may be more translationally valid and predictive of antidepressant treatment outcome. Chronic corticosterone (CORT) administration is a well-validated pharmacological stressor that increases avoidance in negative valence behaviors associated with anxiety
Identifiants
pubmed: 31822658
doi: 10.1038/s41398-019-0674-4
pii: 10.1038/s41398-019-0674-4
pmc: PMC6904464
doi:
Substances chimiques
Steroids
0
Corticosterone
W980KJ009P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
337Subventions
Organisme : NIMH NIH HHS
ID : R01 MH112861
Pays : United States
Références
Biol Psychiatry. 2006 Jun 15;59(12):1151-9
pubmed: 16566899
Biol Psychiatry. 2008 Feb 15;63(4):353-9
pubmed: 17889834
Nat Neurosci. 2015 Oct;18(10):1394-404
pubmed: 26404714
J Psychiatry Neurosci. 2015 Jul;40(4):219-21
pubmed: 26107348
Biol Psychiatry. 2008 May 1;63(9):847-51
pubmed: 18005940
Science. 2009 Jul 31;325(5940):621-5
pubmed: 19644122
Curr Top Behav Neurosci. 2016;28:231-62
pubmed: 26873017
Biol Psychiatry. 2013 Apr 1;73(7):639-45
pubmed: 23228328
PLoS One. 2013;8(3):e58693
pubmed: 23533587
Neuropsychopharmacology. 2005 Jun;30(6):1138-47
pubmed: 15689962
Biol Psychiatry. 2008 Nov 15;64(10):884-90
pubmed: 18675955
Psychoneuroendocrinology. 2010 Aug;35(7):977-86
pubmed: 20071096
J Affect Disord. 2003 Mar;74(1):5-13
pubmed: 12646294
J Comp Physiol Psychol. 1955 Aug;48(4):285-93
pubmed: 13252159
Neuron. 2009 May 28;62(4):479-93
pubmed: 19477151
Neuropsychopharmacology. 2010 May;35(6):1290-301
pubmed: 20107431
J Neurosci. 2002 Jun 1;22(11):4563-7
pubmed: 12040063
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20714-9
pubmed: 23185000
Curr Protoc Neurosci. 2009 Oct;Chapter 9:Unit 9.32
pubmed: 19802817
JAMA Psychiatry. 2013 May;70(5):499-507
pubmed: 23487253
Neuropharmacology. 2012 Nov;63(6):1012-21
pubmed: 22824190
Exp Clin Psychopharmacol. 2017 Apr;25(2):94-104
pubmed: 28287792
J Neurosci Methods. 1985 Aug;14(3):149-67
pubmed: 2864480
Psychopharmacology (Berl). 2013 Feb;225(3):569-77
pubmed: 22983097
Biol Psychiatry. 2017 Feb 15;81(4):366-377
pubmed: 26786312
Neuroimage. 2008 Sep 1;42(3):1118-26
pubmed: 18586109
Psychopharmacology (Berl). 2002 Sep;163(2):121-41
pubmed: 12202959
J Appl Behav Anal. 2001 Summer;34(2):145-66
pubmed: 11421308
Science. 2004 Dec 10;306(5703):1940-3
pubmed: 15528409